These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29669052)

  • 21. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
    Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy.
    Greveson K; Goodhand J; Capocci S; Woodward S; Murray C; Cropley I; Hamilton M; Lipman M
    J Crohns Colitis; 2013 Jun; 7(5):412-8. PubMed ID: 23009739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
    Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
    J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.
    Matsumoto H; Ohfuji S; Watanabe K; Yamagami H; Fukushima W; Maeda K; Kamata N; Sogawa M; Shiba M; Tanigawa T; Tominaga K; Watanabe T; Fujiwara Y; Hirota Y; Arakawa T
    J Gastroenterol; 2015 Aug; 50(8):876-86. PubMed ID: 25672513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
    Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.
    Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
    Aliment Pharmacol Ther; 2017 Mar; 45(5):653-659. PubMed ID: 28074487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical guidelines for the treatment of inflammatory bowel disease.
    Kuhbacher T; Fölsch UR
    World J Gastroenterol; 2007 Feb; 13(8):1149-55. PubMed ID: 17451192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
    Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
    Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States.
    Lin KK; Sewell JL
    Am J Gastroenterol; 2013 Dec; 108(12):1824-30. PubMed ID: 24300857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study.
    Bon L; Scharl S; Vavricka S; Rogler G; Fournier N; Pittet V; Scharl M; Greuter T; Schreiner P; Frei P; Misselwitz B; Biedermann L; Zeitz J;
    PLoS One; 2019; 14(4):e0215738. PubMed ID: 31022217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
    Guilcher K; Fournier N; Schoepfer A; Schibli S; Spalinger J; Braegger C; Nydegger A;
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1159-1167. PubMed ID: 29985208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.
    Koutroubakis IE; Ramos-Rivers C; Regueiro M; Koutroumpakis E; Click B; Schwartz M; Swoger J; Baidoo L; Hashash JG; Barrie A; Dunn MA; Binion DG
    Inflamm Bowel Dis; 2015 Jul; 21(7):1587-93. PubMed ID: 25933393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
    Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
    Singh H; Nugent Z; Demers AA; Bernstein CN
    Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
    Cosnes J
    Dig Dis; 2017; 35(1-2):50-55. PubMed ID: 28147366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of cancer treatment on inflammatory bowel disease remission and reactivation.
    Axelrad JE; Fowler SA; Friedman S; Ananthakrishnan AN; Yajnik V
    Clin Gastroenterol Hepatol; 2012 Sep; 10(9):1021-7.e1. PubMed ID: 22732273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.